Germany-wide personalised medicine study for high-risk paediatric cancer patients.
Comprehensive sequencing and analysis is feasible in clinically relevant time frame.
Half of patients across entities harbored a reasonable confidence druggable target.
Cases of clinical response to targeted agents demonstrate proof of principle.
This model can expand paediatric access to molecular profiling and targeted therapies.